Antiviral Therapy · 2014 · 13 citations · 34 references
Life SciencesImmunologyInflammationMemoryNeuroimmunologyAntiretroviral TherapyCognitive ImpairmentCardiovascular Risk MarkersCardiovascular Risk StratificationCognitive PerformanceCognitive Performance ImpairmentCognitive Performance TestingCognitive Status AssessmentHiv-associated Cognitive ImpairmentNeuropsychological Batteries
BACKGROUND: The aim of our study was to better understand the dynamics between cardiovascular risk factors and immunological parameters in the evolution of cognitive performance in HIV+ patients. METHODS: We conducted a prospective longitudinal study, consecutively enrolling asymptomatic HIV+ subjects during routine outpatient visits at two clinical centres. At baseline and after 2 years, all patients underwent a comprehensive neuropsychological battery. Common carotid intima-media thickness (cIMT) was also measured. RESULTS: A total of 150 patients completed the study (77% males, median age 46 years, 20% with past AIDS-defining events, 95% on cART, 88% with HIV-RNA<50 copies/ml). After a 2-year follow-up, there was no difference in the proportion of patients with cognitive impairment (32% versus 33% at baseline; P=1.00). However, a significantly worse memory performance was observed (z score mean change -0.51, sd 1.05; P=0.001). At multivariate analysis, baseline dyslipidaemia (OR 2.7, 95% CI 1.1, 7.1; P=0.037) showed a significant association with a higher risk of memory impairment at 2-year follow-up, while higher baseline CD4(+) T-cell count (OR 0.80 per 100 cells/μl higher; 95% CI 0.66, 0.97; P=0.026) was found to be a protective factor, adjusting for the presence of a memory impairment at baseline. When the analysis was restricted to patients who did not change antiretroviral therapy during the study period (n=109), baseline cIMT (OR 14.6 per 0.1 mm higher; 95% CI 1.1, 189.9; P=0.041) also emerged as an independent risk factor for memory impairment at 2-year follow-up. CONCLUSIONS: Immunological parameters and cardiovascular risk factors are independently associated with the evolution of cognitive status in HIV+ patients.
34
Updated research nosology for HIV-associated neurocognitive disorders
Andrea Antinori, Gabriele Arendt, James T. Becker et al. · Neurology · 2007 · 2.6K citations
Medicine, Neurology, Neuroscience +14
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy
Robert K. Heaton, David B. Clifford, Donald Franklin et al. · Neurology · 2010 · 2.3K citations · Full text
Medicine, Neurology, Psychiatry +17